Annals of Indian Academy of Neurology
LETTER TO THE EDITOR
Year
: 2016  |  Volume : 19  |  Issue : 4  |  Page : 528-

Vitamin D deficiency in antiphospholipid syndrome


Nataraja Pillai Venugopal 
 Department of Neuro-ophthalmology Clinic and Glaucoma Service, AG Eye Hospital, Trichy, Tamil Nadu, India

Correspondence Address:
Nataraja Pillai Venugopal
AG Eye Hospital, Puthur, Trichy - 620 017, Tamil Nadu
India




How to cite this article:
Venugopal NP. Vitamin D deficiency in antiphospholipid syndrome.Ann Indian Acad Neurol 2016;19:528-528


How to cite this URL:
Venugopal NP. Vitamin D deficiency in antiphospholipid syndrome. Ann Indian Acad Neurol [serial online] 2016 [cited 2020 Sep 26 ];19:528-528
Available from: http://www.annalsofian.org/text.asp?2016/19/4/528/194464


Full Text

Sir,

We read with interest the article titled "Antiphospholipid syndrome is an important modifiable risk factor of stroke in the young" by Khan. [1] We appreciate the author's effort and research work. We would like to highlight a few points regarding ocular findings and the role of vitamin D supplementation in antiphospholipid syndrome (APS). Ophthalmic manifestations of APS are transient monocular blindness, branch retinal artery occlusion, central retinal artery, and vein occlusion and choriocapillary occlusion. Iritis, scleritis, keratitis, vitritis, posterior scleritis, retinal detachment, occipital lobe ischemia, and migraine-like disturbance have also been reported. [2] Tugcu et al. [3] reported a case of nonarteritic anterior ischemic optic neuropathy as the presenting manifestation of APS. In our neuro-ophthalmological clinical practice, we observed a recovered case of stroke in a young person due to APS, presenting with residual permanent homonymous hemianopia. Khan [1] has highlighted the importance of developing a research tool to ameliorate and prevent APS-induced vascular brain damage. Vitamin D deficiency is common among APS patients and it is associated with clinically defined thrombotic event. [4] Hypovitaminosis D may have a complex origin in APS and may be part of a mosaic of factors that contribute to autoimmunity rather than a consequence of chronic disease and treatment. To conclude, the prognostic value of vitamin D deficiency and therapeutic value of supplementation in APS patients should be clarified by prospective studies.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Khan S. Antiphospholipid syndrome is an important modifiable risk factor for stroke in the young. Ann Indian Acad Neurol 2015;18:359-60.
2Vaphiades MS, Brock W, Brown HH, Petursson G, Westfall CT. Catastrophic antiphospholipid antibody syndrome manifesting as orbital ischemic syndrome. J Neuroophthalmol 2001;21: 260-3.
3Tugcu B, Acar N, Coskun CT, Celik S, Yigit FU. Nonarteritic anterior ischemic optic neuropathy as the presenting manifestation of primary antiphospholipid syndrome. Indian J Ophthalmol 2014;62:642-4.
4Venugopal N. Vitamin D supplementation in antiphospholipid syndrome patients. Indian J Ophthalmol 2015;63:82.